ICG-enhanced TTT effectively treats retinoblastoma

Article

Indocyanine green (ICG) enhanced transpupillary thermotherapy (TTT) in combination with ophthalmic artery chemosurgery can effectively treat retinoblastoma refractory without ocular side effects, claims a study.

Indocyanine green (ICG) enhanced transpupillary thermotherapy (TTT) in combination with ophthalmic artery chemosurgery can effectively treat retinoblastoma refractory without ocular side effects, claims a study.

The single centre, retrospective study, performed by Dr David H Abramson, Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Centre, New York, USA, included 16 eyes of 13 retinoblastoma patients treated with TT and ICG using an indirect ophthalmoscope. The outcome measures were tumour response and electroretinogram.

After treatment significant tumour regression was seen in all eyes. Well-differentiated characteristics were seen in 13 eyes, two eyes had implanting vitreous seeds and one eye was refractory to traditional TT.

All eyes retained ERG function. Meaning ICG-enhanced TTT with ophthalmic artery chemosurgery can treat retinoblastoma, similarly to conventional focal treatments.

The abstract can be viewed in the latest edition of British Journal of Ophthalmology.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.